NCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
142 trialsNCT02166463 2026-03-18
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting
NCT03914625 2026-03-18
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT06124157 2026-03-13
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06717347 2026-03-13
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06091254 2026-03-11
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06191744 2026-03-03
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT03150693 2026-03-02
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT04685616 2026-02-18
RADAR
University College, London
Phase 3 Recruiting
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT06356129 2026-02-12
GOLSEEK-1
Celgene
Phase 3 Active not recruiting
NCT01516580 2026-02-09
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT03274492 2026-02-06
POLARIX
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06006117 2025-12-19
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT06911502 2025-12-05
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT03907488 2025-12-04
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07258680 2025-12-02
BrEto-TCL
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Enrolling by invitation
NCT02112916 2025-12-01
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02883049 2025-11-26
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06072131 2025-10-23
CRESCENDO
Acrotech Biopharma Inc.
Phase 3 Recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT06947967 2025-09-15
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT04824092 2025-09-08
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT03159897 2025-08-08
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT00002462 2025-08-05
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT00049595 2025-08-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00379041 2025-08-05
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT00408005 2025-04-20
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT03643276 2025-04-06
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
Phase 3 Recruiting
NCT04043494 2025-03-21
LBL 2018
University Hospital Muenster
Phase 3 Recruiting
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT04231448 2024-12-05
DEB
Chipscreen Biosciences, Ltd.
Phase 3 Active not recruiting
NCT02406092 2024-11-21
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
Phase 3 Completed
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT04638790 2024-09-27
HL-Russia-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 3 Recruiting
NCT00991211 2024-08-22
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
Phase 3 Completed